ReviewPharmaceutical science advances2025
Artificial intelligence in human immunodeficiency virus mutation prediction and drug design: Advancing personalized treatment and prevention.
Review in Pharmaceutical science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Anti-HIV Potential ofViruses · 2026Article
- Advancing Human-Centered AI in Clinical Decision Support: Sociocognitive Human-in-the-Loop Study in HIV Care.Journal of medical Internet research · 2026Article
- Review
- HIV-1 and Artificial Intelligence: From Molecular Insight to Population Impact.Journal of AIDS and HIV treatment · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite significant advancements in highly active antiretroviral therapy (HAART), Human Immunodeficiency Virus (HIV) remains a global health challenge due to its high mutation rate, drug resistance, and the complexity of treatment optimization. Artificial intelligence (AI) has emerged as a transformative tool in HIV research, offering innovative solutions for predicting viral mutations, optimizing drug discovery and formulation design. However, challenges such as limited access to diverse datasets, ethical concerns, and model interpretability hinder the full potential of AI in HIV research. This review highlights gaps in AI-driven HIV research and explores advancements to address these challenges. AI-driven platforms, such as DeepHIV and geno2pheno, have demonstrated success in forecasting resistance mutations and guiding therapeutic decisions. AI is also revolutionizing drug formulation development by enhancing solubility, bioavailability, and stability, while improving patient adherence through advanced delivery systems. Current applications of AI in HIV mutation prediction, drug discovery, and formulation optimization have highlighted the potential of AI towards HIV management and eradication while addressing gaps in data availability and model transparency. By integrating structural, pharmacological, and clinical data, AI provides a comprehensive framework for rational drug design and personalized treatment strategies. By leveraging AI-driven insights, HIV treatment and prevention can become more personalized, efficient, and sustainable. Future research should focus on overcoming data limitations, enhancing model interpretability, and exploring innovative AI approaches to contribute to the global fight against the HIV epidemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.